Clinical trials: RNA
Coronavirus Infection, SARS (Severe Acute Respiratory Syndrome)
Comparison of Tocilizumab Plus Dexamethasone vs. Dexamethasone for Patients With Covid-19
The overall objective of the study is to determine the therapeutic effect and tolerance of Tocilizumab combined with Dexamethasone in patients with moderate, severe pneumonia or critical pneumonia associated with Coronavirus…
- Conditions
- Coronavirus Infection, SARS (Severe Acute Respiratory Syndrome), Virus Diseases, Coronaviridae Infections
- Trial name
- TOCIDEX (NCT04476979)
- Testing
- Tocilizumab, Dexamethasone
- Where
- French Guiana
- Volunteers
- 453 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Hepatitis, Hepatitis C
Efficacy and Safety of Grazoprevir (+) Uprifosbuvir (+) Ruzasvir (MK-3682B) (MK-5172 + MK-3682 + MK-8408) Fixed Dose Combination in Chronic HCV Participants Failing Prior Antiviral Treatment (MK-3682-021)
This is a randomized, multicenter, 2-part, open-label trial of the combination regimen of grazoprevir (GZR [MK-5172]; 100mg), uprifosbuvir (UPR [MK-3682]; 450 mg) and ruzasvir (RZR [MK-8408]; 60 mg) with and without Ribavirin…
- Conditions
- Hepatitis, Hepatitis C, Digestive System Diseases, Flaviviridae Infections
- Trial name
- NCT02613403
- Testing
- MK-3682B, Ribavirin
- Volunteers
- 94 people
- Sponsor
- Merck Sharp & Dohme LLC
Influenza, SARS (Severe Acute Respiratory Syndrome)
Predicting Severity and Disease Progression in Influenza-like Illness (Including COVID-19)
Respiratory infections such as colds, flu and pneumonia affect millions of people around the world every year. Most cases are mild, but some people become very unwell.
- Conditions
- Influenza, SARS (Severe Acute Respiratory Syndrome), Respiratory Viral Infection, Respiratory Tract Infections
- Trial name
- PREDICT-ILI (NCT04664075)
- Testing
- Respiratory infections
- Where
- United Kingdom
- Volunteers
- 8 people
- Sponsor
- Imperial College London
Covid19
Vaccination for Recovered Inpatients With COVID-19 (VATICO)
In this Phase 4, open-label trial, participants of the ACTIV-3/TICO clinical trial at selected sites who received certain pre-specified blinded investigational agents or placebo as part of that trial, and who have since achieved…
- Trial name
- NCT04969250
- Testing
- Moderna mRNA-1273 COVID-19 vaccine, Pfizer BNT162b2 COVID-19 vaccine
- Where
- 30 sites in United States, Nigeria and 4 more
- Volunteers
- 66 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Viral Infection
Study to Determine the Safety, Tolerability and Pharmacokinetics of UV-4B Solution Administered Orally in Healthy Subjects
The objective is to evaluate the safety and tolerability of a single-ascending oral dose of UV-4B in healthy subjects and to determine pharmacokinetic parameters describing absorption and elimination following a single dose of…
- Trial name
- UV (NCT02061358)
- Testing
- UV-4B 3 mg, UV-4B 10 mg, UV-4B 30 mg
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Emergent BioSolutions
Viral Infection
Safety and Pharmacokinetics of UV-4B Solution Administered Orally as Multiple Ascending Doses to Healthy Subjects
The purpose of this study is to evaluate the safety and pharmacokinetics of UV-4B oral solution when administered to healthy subjects three times a day (TID) for 7 days.
- Trial name
- NCT02696291
- Testing
- UV-4B 30 mg oral solution, UV-4B 75 mg oral solution, UV-4B 150 mg oral solution
- Where
- 2 sites in United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Emergent BioSolutions
COVID-19
PF-07304814 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)
This study looks at the safety and effectiveness of PF-07304814 in treating COVID-19 in people who have been hospitalized with the infection.
- Trial name
- NCT05780541
- Testing
- PF-07304814, Remdesivir
- Where
- 40 sites in United States, Denmark
- Volunteers
- 58 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
COVID-19
BRII-196/BRII-198 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)
This study looks at the safety and effectiveness of BRII-196/BRII-198 in treating COVID-19 in people who have been hospitalized with the infection.
- Trial name
- NCT05780424
- Testing
- BRII-196, BRII-198, Remdesivir
- Where
- 107 sites in United States, Denmark and 6 more
- Volunteers
- 353 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
COVID-19
MP0420 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)
This study looks at the safety and effectiveness of MP0420 in treating COVID-19 in people who have been hospitalized with the infection.
- Trial name
- NCT05780463
- Testing
- MP0420, Remdesivir
- Where
- 105 sites in United States, Denmark and 8 more
- Volunteers
- 485 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Zika Virus, Zika Virus Infection
VRC 705: A Zika Virus DNA Vaccine in Healthy Adults and Adolescents
This was a multicenter, randomized study to evaluate the safety, immunogenicity, and efficacy of VRC-ZKADNA090-00-VP (Zika virus wildtype DNA vaccine) or placebo.
- Conditions
- Zika Virus, Zika Virus Infection, Virus Diseases, Flavivirus Infections
- Trial name
- DNA (NCT03110770)
- Testing
- VRC-ZKADNA090-00-VP, VRC-PBSPLA043-00-VP
- Where
- 17 sites in United States, Brazil and 7 more
- Volunteers
- 2,428 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Coinfection, Aids/Hiv Problem
Study of Interferon-Gamma in the Complex Treatment of Patients Infected With HIV and Tuberculosis
The primary purpose of this study is to assess the safety and efficacy of interferon-gamma by subcutaneous injection in complex treatment of patients with co-infection of HIV and pulmonary tuberculosis and to determine the…
- Conditions
- HIV Coinfection, Aids/Hiv Problem, Tuberculosis, Pulmonary, Human Immunodeficiency Virus
- Trial name
- MSPB_TB (NCT05065905)
- Testing
- Interferon-Gamma
- Where
- 2 sites in Russia
- Volunteers
- 78 people
- Sponsor
- SPP Pharmaclon Ltd.
COVID-19
LY3819253 (LY-CoV555) for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)
This study looks at the safety and effectiveness of LY3819253 in treating COVID-19 in people who have been hospitalized with the infection.
- Trial name
- NCT05780268
- Testing
- LY3819253, Remdesivir
- Where
- 57 sites in United States, Denmark and 2 more
- Volunteers
- 314 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
COVID-19
VIR-7831 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)
This study looks at the safety and effectiveness of VIR-7831 in treating COVID-19 in people who have been hospitalized with the infection.
- Trial name
- NCT05780281
- Testing
- VIR-7831, Remdesivir
- Where
- 105 sites in United States, Denmark and 6 more
- Volunteers
- 367 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Acquired Immunodeficiency Syndrome, HIV Infection
Clinic-based ART Diagnostic Evaluation
The study is funded through the Office of the Global AIDS Coordinator (OGAC #KE-07-0044). The purpose of this study is two-fold.
- Conditions
- Acquired Immunodeficiency Syndrome, HIV Infection, RNA Virus Infections, Virus Diseases
- Trial name
- CLADE (NCT01791556)
- Testing
- HIV-1 viral load testing
- Where
- Kenya
- Volunteers
- 820 people
- Sponsor
- Walter Reed Army Institute of Research (WRAIR)
Periodontal Disease, AVDC Stage 3and 4, Epithelial Mesenchymal Transition
The Potential Association of Long Non-coding RNA (NEAT1 and MALAT1) in the Process of Epithelial-mesenchymal Transition in Periodontitis
Periodontitis is a polymicrobial, inflammatory condition affecting tooth-supporting tissues. It is characterized by a progressive loss of epithelial attachment and resorption of alveolar bone, which can lead to tooth loss.
- Conditions
- Periodontal Disease, AVDC Stage 3and 4, Epithelial Mesenchymal Transition, Long Noncoding RNA
- Trial name
- NCT05995067
- Testing
- periodontitis challenge
- Where
- Iraq
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Ali A Abdulkareem
HIV Infections, Sexually Transmitted Diseases
Integrating Enhanced HIV PrEP Into a STI Clinic in Lilongwe
This is a prospective cohort study evaluating acceptability, feasibility, and effectiveness of integrating HIV pre-exposure prophylaxis (PrEP) into a sexually transmitted infection (STI) clinic alongside assisted partner…
- Conditions
- HIV Infections, Sexually Transmitted Diseases, Blood-Borne Infections, Communicable Disease
- Trial name
- NCT05307991
- Testing
- PrEP, STI testing, Assisted partner notification
- Where
- Malawi
- Volunteers
- 249 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
COVID-19 Pneumonia, Sequelae of; Infection
Assessment of Long-term Sequelae of Coronavirus Disease 2019 (COVID-19) Pneumonia With Chest CT and Pulmonary Function Tests
The goal of this prospective multicentric study is to evaluate the presence of long-term pulmonary sequelae in patients who had required hospitalization for treating COVID-19 pneumonia, trough chest CT and pulmonary function…
- Conditions
- COVID-19 Pneumonia, Sequelae of; Infection, Respiratory Function Impaired, SARS CoV 2 Infection
- Trial name
- NCT05835128
- Where
- 2 sites in Portugal
- Volunteers
- 250 people
- Sponsor
- Centro Hospitalar Universitario do Algarve
Urothelial Carcinoma Associated 1 RNA, Human
Study of Pembrolizumab With or Without Platinum-based Combination Chemotherapy Versus Chemotherapy Alone in Urothelial Carcinoma (MK-3475-361/KEYNOTE-361)
The purpose of this study is to determine the efficacy and safety of pembrolizumab (pembro, MK-3475) with or without chemotherapy versus chemotherapy alone in participants with advanced or metastatic urothelial carcinoma (bladder…
- Trial name
- NCT02853305
- Testing
- Pembrolizumab, Cisplatin, Carboplatin
- Volunteers
- 1,010 people
- Sponsor
- Merck Sharp & Dohme LLC
Covid19
ACTIV-3: Therapeutics for Inpatients With COVID-19
This study looks at the safety and effectiveness of different drugs in treating COVID-19 in people who have been hospitalized with the infection.
- Trial name
- TICO (NCT04501978)
- Testing
- LY3819253, Remdesivir, VIR-7831
- Where
- 135 sites in United States, Denmark and 8 more
- Volunteers
- 2,753 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Virus Diseases, RNA Virus Infections
Efficacy, Safety, and Immunogenicity of a Plant-Derived Quadrivalent Virus-Like Particles (VLPs) Influenza Vaccine in Adults
This Phase 3 study is intended to assess the efficacy of the Quadrivalent VLP Influenza Vaccine during the 2017-2018 influenza season in healthy adults 18 to 64 years of age.
- Conditions
- Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases, Respiratory Tract Infections
- Trial name
- NCT03301051
- Testing
- Quadrivalent VLP Vaccine
- Where
- 73 sites in United States, Canada and 5 more
- Volunteers
- 10,160 people, healthy volunteers welcome
- Sponsor
- Medicago